Log in or Sign up for Free to view tailored content for your specialty!
Neurology News
Herpes simplex virus 1 may be associated with increased risk for Alzheimer's, dementia
Mounting evidence suggests that herpes simplex virus 1 may be associated with an increased risk for Alzheimer’s disease and dementia, according to a systematic review of published studies.
Quantification of amyloid PET scans feasible, consistent with visual analysis in AD
For clinicians who treat patients with Alzheimer’s disease, quantification of amyloid positron emission tomography was feasible and possessed a high degree of concordance with visual analysis, according to a presentation at CTAD.
Log in or Sign up for Free to view tailored content for your specialty!
FDA approves Agamree for Duchenne muscular dystrophy
The FDA has approved a 40 mg/mL oral suspension of Agamree to treat Duchenne muscular dystrophy in patients aged 2 years and older, according to a release from the manufacturer.
Technology use highly accepted by caregivers, those with AD-related agitation
Technology was found to be both easy to use and highly acceptable in a cohort of those with Alzheimer’s-related agitation and their caregivers, according to a poster presentation at CTAD.
Customized transcription linked to more accurate speech-based AD screening
A customized speech transcription model logged roughly 30% fewer errors compared with manual or automated methods and may be a more effective tool in assessing verbal Alzheimer’s disease-related impairment.
Computerized training improved cognitive performance in those with MCI
Individuals with mild cognitive impairment performed faster on functional skills assessments and logged fewer dropouts when undergoing concurrent burst cognitive training, according to a poster from CTAD.
Participation in digital cognitive test, biomarker assays linked to AD study enrollment
Participation in memory-based digital cognitive testing and blood-based biomarker assays for Alzheimer’s-related pathology was linked to successful enrollment into clinical trials for disease-modifying treatment, according to research.
Donanemab slows disease progression, reduces amyloid in early symptomatic Alzheimer’s
Compared with placebo, donanemab slowed disease progression and reduced amyloid presence at 76 weeks for carriers and noncarriers of the APOE ε4 allele in early symptomatic Alzheimer’s disease, according to data presented at CTAD.
First patient dosed in study of synthetic psychedelic for treatment-resistant depression
Beckley Psytech announced dosing of the first patient in a phase 2b clinical trial of BPL-003, an intranasal synthetic formulation of the psychedelic compound 5-MeO-DMT for treatment-resistant depression.
CDC: Burnout in health care workers ‘has reached crisis levels’
Health care workers face an escalating mental health crisis that is made worse by increased harassment, according to results from a new CDC Vital Signs report.
-
Headline News
NIH finds neuroscience director engaged in research misconduct
September 26, 20241 min read -
Headline News
Q&A: Phone app uses AI technology to personalize allergy forecasts
September 25, 20243 min read -
Headline News
FDA grants fast track designation to brepocitinib for noninfectious uveitis
September 25, 20241 min read
-
Headline News
NIH finds neuroscience director engaged in research misconduct
September 26, 20241 min read -
Headline News
Q&A: Phone app uses AI technology to personalize allergy forecasts
September 25, 20243 min read -
Headline News
FDA grants fast track designation to brepocitinib for noninfectious uveitis
September 25, 20241 min read